537 related articles for article (PubMed ID: 16096879)
1. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
2. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
3. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
4. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
5. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
7. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
[TBL] [Abstract][Full Text] [Related]
8. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
10. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
[TBL] [Abstract][Full Text] [Related]
11. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
12. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
13. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
14. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
Creatsa M; Pliatsika P; Kaparos G; Antoniou A; Armeni E; Tsakonas E; Panoulis C; Alexandrou A; Dimitraki E; Christodoulakos G; Lambrinoudaki I
J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
[TBL] [Abstract][Full Text] [Related]
15. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
16. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
17. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Takata S; Abbaspour A; Yonezu H; Yasui N
J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
[TBL] [Abstract][Full Text] [Related]
18. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
19. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
[TBL] [Abstract][Full Text] [Related]
20. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
